Real-world clinical outcomes among avelumab-treated patients with advanced MCC
| Treatment on index date | Avelumab or avelumab +systemic therapy (N=90) | Avelumab only (n=86) | Avelumab+systemic therapies (n=4) | Patients received avelumab as 1L treatment (n=73) | Patients received avelumab as 2L+ treatment (n=17) |
| rwDOR | NE (NE to NE) | NE (NE to NE) | NE (NE to NE) | NE (NE to NE) | 4.6 (1.1 to NE) |
| rwPFS | 24.4 (8.3 to NE) | 24.4 (6.4 to NE) | NE (NE to NE) | 36.1 (9.3 to NE) | 6.4 (4.5 to NE) |
| OS | 30.7 (11.2 to NE) | 25.7(9.7 to NE) | NE (NE to NE) | 41.7 (10.2 to NE) | 15.9 (4.3 to NE) |
Estimates represent median (95% CI) in months.
1L, first line; 2L+, second or later line; MCC, Merkel cell carcinoma; NE, not estimable; OS, overall survival; rwDOR, real-world duration of response; rwPFS, real-world progression-free survival.